Kinetics and involvement of interleukin-17 in the outcome of peritonitis in nondiabetic patients undergoing peritoneal dialysis  by Wang, Hsin-Hui et al.
Available online at www.sciencedirect.comJournal of the Chinese Medical Association 74 (2011) 11e15
www.jcma-online.comOriginal Article
Kinetics and involvement of interleukin-17 in the outcome of peritonitis in
nondiabetic patients undergoing peritoneal dialysis*
Hsin-Hui Wang a,b,y, Tzong-Yann Lee c,d,y, Ching-Yuang Lin e,f,*
aDepartment of Pediatrics, Division of Nephrology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC
bDepartment of Pediatrics, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC
cDepartment of Internal Medicine, Division of Nephrology, En Chu Kong Hospital, Taipei, Taiwan, ROC
dDepartment of Integrated Diagnostics & Therapeutics, National Taiwan University Hospital, Taipei, Taiwan, ROC
eClinical Immunological Center, and Division of Pediatric Nephrology, China Medical University Hospital, Taichung, Taiwan, ROC
fCollege of Medicine, China Medical University, Taichung, Taiwan, ROC
Received 24 June 2010; accepted 4 August 2010AbstractBackground: Peritonitis is the most serious complication of peritoneal dialysis (PD). We previously showed that high levels of interleukin (IL)-12
and IL-18 in PD effluents (PDE) during the early phase of peritonitis correlated with a predominant Type 1 immune response and a favorable
outcome in PD-related peritonitis. To further clarify the longitudinal changes of peritoneal immunity during PD-related peritonitis, we examined the
kinetic production of IL-17 in PDE during peritonitis. The correlation between the IL-17 expression pattern and peritonitis outcome was analyzed.
Methods: The levels of IL-17 were measured in PDE during various phases of peritonitis in 38 patients undergoing PD. The patients were
divided into two groups, according to whether they had a rapid versus a delayed response to antibiotic treatment.
Results: The kinetic expression of IL-17, as measured by enzyme-linked immunosorbent assay, differed between the two groups. In the rapid
response group, high level of IL-17 was detected in PDE initially and progressively decreased during treatment. In the delayed response group,
IL-17 levels in PDE were persistently low throughout the whole course of treatment. In the early phase of peritonitis, the IL-17 levels in PDE
were significantly higher in the rapid response group ( p< 0.05).
Conclusion: These data suggested that local IL-17 production is part of a protective early immune response to PD-related peritonitis. High levels
of IL-17 in PDE during the early phase of peritonitis correlated with a favorable outcome. Manipulation of IL-17 cytokine expression in patients
with peritonitis may modulate peritoneal immune response and affect peritonitis outcome.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Peritoneal dialysis (PD) is an established treatment for end-
stage renal disease. Peritonitis is themost serious complication of
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doi:10.1016/j.jcma.2011.01.002undergoing PD2 and is the major cause of hospitalization, cath-
eter loss, and technique failure.3 Approximately 20e42% of
peritonitis infections are refractory to appropriate antibiotic
therapy,1,4,5 and the mechanisms by which these bacterial
infections cause refractory peritonitis are unknown. In addition to
differences in the organisms causing the infection,6 another
possibility is a deficient host peritoneal defense response.7 In
a previous study,8 we found that a progressive increase in CD4/
CD8 ratio in PD effluents (PDE) was an indicator of favorable
outcome. We also found that a predominant Type 1 T-cell
immune response correlated with a favorable outcome during
peritonitis.9,10Chinese Medical Association. All rights reserved.
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lated by a complex interaction between immunocompetent cells
and a network of cytokines and chemokines.11,12 Examination
of intraperitoneal levels of inflammatory mediators has
demonstrated that these levels are increased during acute
episodes of peritonitis and subsequently return to control lev-
els.12e14We found that high levels of interleukin (IL)-12 and IL-
18 in PDE during the early phase of peritonitis correlated with
a predominant Type 1 immune response and a favorable
outcome.9,10 These studies revealed that local secretion of
inflammatory mediators is an important component in the
control and outcome of peritoneal infection.12 Examination of
the differences in the expression of cytokines during peritoneal
immune responses may provide insights into the roles of the
cytokines in the outcomes of peritonitis.
IL-17 is a potent proinflammatory cytokine. It has been known
to be produced by a newly identified subset of activated CD4þ T
celldTh17. Expression of IL-17 has also been detected in some
other cell types, including CD8þ T cells, gd T cells, and natural
killer T cells (NKT cells), in some circumstances.15,16 Accu-
mulating evidence indicates that IL-17 is involved in the induc-
tion and progression of inflammatory diseases. Through IL-17
receptor-mediated signal pathway, IL-17 can stimulate the
production of IL-6, IL-8, tumor necrosis factors (TNF-a), gran-
ulocyte colony-stimulating factor (G-CSF) and chemokines
(CXC) chemokines, which regulate neutrophil migration and
recruitments.17 IL-17 can also induce the production of antimi-
crobial peptides against infection.18 Although initial findings
showed that IL-17 could not be classified to the Th1/Th2 para-
digm, recent studies showed the important role of IL-17 in the
Th1 and Th2 immune responses.19e22 Using animal model,
Witowski et al.23 reported that IL-17 was capable of selectively
recruiting neutrophils into the peritoneal cavity through the
release of neutrophil-specific chemokines from the peritoneal
mesothelium. However, no report has been published on the in
vivoproduction of IL-17 inPDEduringperitonitis, and the role of
IL-17 in the outcome of PD-related peritonitis is also unknown.
To explore the impact of IL-17 cytokine on the peritoneal
immune response during peritonitis, we examined the longi-
tudinal kinetic changes in IL-17 levels in PDE. We undertook
a prospective study to evaluate IL-17 levels in PDE produced
by patients with PD peritonitis and compared them among
patients with different treatment outcomes.
2. Methods2.1. Patient populationThirty-eight consenting patients with end-stage renal
disease (20 men and 18 women) treated with PD and with
a history of peritonitis were included in this study. All patients
had a Tenckhoff peritoneal catheter inserted and were treated
with the standard double-bag system (Baxter Healthcare
Corp., Deerfield, IL, USA). The daily dietary protein intake
was 1.2e1.5 g/kg, and the caloric intake was 35e45 kcal/kg,
including the absorption from the dialysate, calculated at
3.8 kcal/g of dextrose. Vitamin supplements, includingvitamin B complex, were prescribed to each patient. The
exclusion criteria included the following: (1) tunnel-tract or
exit-site infections, (2) completion of antibiotic therapy for
peritonitis within 28 days of study enrollment, (3) the presence
of peritonitis attributed to fungal or mycobacterial infection or
negative culture, (4) drug sensitivity showing resistance to
initial antibiotic therapy, (5) previous immunosuppressive
therapy, (6) anemia from a disorder other than chronic renal
failure, and (7) insulin-dependent diabetes mellitus. The
dialysis and overall clinical management were prescribed by
nephrologists. Patients used 1.5-L or 2-L PD bags, with four
daily exchanges. The glucose solution concentrations and the
exchange times were held constant during the study.2.2. Peritonitis and response to treatmentPeritonitis was defined as the presence of two of the
following criteria: microorganisms on gram staining; subse-
quent positive culture of PD fluid; cloudy fluid (leukocyte
count, >100 cells/mL with >50% polymorphonuclear cells);
and/or peritoneal inflammation symptoms. Episodes of peri-
tonitis were treated according to a standard protocol. The
initial antibiotic regimen included the intraperitoneal admin-
istration of teicoplanin and a third-generation cephalosporin,
which was modified on the basis of organism identification
and drug sensitivities.
Patients were divided into two groups according to their
clinical response. A rapid clinical response was defined as the
resolution of symptoms of peritonitis, including disappearance
of abdominal pain and clearing of the peritoneal dialysate
within 72 hours of initiation of antibiotic therapy, followed by
complete recovery within 7e10 days of initiation of treatment.
A delayed clinical response refractory to treatment was
defined by the persistence of symptoms, positive dialysate
cultures, and elevated white blood cell count in the dialysate
beyond 72 hours after the initiation of appropriate antibiotic
treatment and followed by a fluctuating and protracted course
over 10e14 days or longer.2.3. Collection of PDEOn Day 0, after onset of symptoms and before the initiation
of antibiotic treatment, bags of PDE were delivered to the
dialysis center of the hospital for routine microbiology labo-
ratory analysis, where 100 mL of PDE fluid was taken asep-
tically for microbiological culture. The bags were resealed and
sent to the research laboratory. During the treatment for
peritonitis, overnight dwell bags of PDE were collected and
processed as described earlier.2.4. Measurements of IL-17 in PDESamples of PDE were centrifuged at 400 g, at 4C for
10 min. After centrifugation, the supernatants were collected
and stored at 70C until assayed. The concentrations of
IL-17 were measured by using commercial enzyme-linked
immunosorbent assay kits (R&D Systems, Mckinley Place,
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sensitivity of the IL-17 assays was 15 pg/mL.2.5. Statistical analysisAll data are presented as mean standard deviation.
Differences between groups were analyzed by the Man-
neWhitney U test. Values of p less than 0.05 were considered
to represent a statistically significant difference.
3. Results3.1. Patient characteristicsThe baseline characteristics of the two study groups are
shown in Table 1. There were 25 patients with rapid clinicalTable 1
Baseline characteristics of patients with rapid versus delayed response to
peritonitis treatment
Group Rapid response
(n¼ 25)
Delayed response
(n¼ 13)
Men/women, n 13/12 7/6
Age, yr
mean SD 42.35 16.42 40.67 13.25
range 12e62 15e59
Dialysis duration, yr
mean SD 3.12 1.21 2.98 1.62
range 1.1e5.3 0.7e5.9
Peritonitis rates, episode/yr,
mean SD
0.56 0.20 0.50 0.30
Underlying disease, n
CGN 15 8
PCK 2 1
HUS 1 d
Reflux nephropathy 2 1
Obstructive nephropathy 2 1
Hypoplasic/dysplasic 1 d
Unknown 2 2
Serum albumin, g/dL
mean SD (range)
3.87 0.36
(3.2e4.4)
3.91 0.23
(3.3e4.5)
Adequacy of dialysis before peritonitis, mean SD
Kt/Vurea (per week)
Renal 0.23 0.28 0.25 0.26
Total 2.25 0.23 2.21 0.25
wCCr (L/wk/1.73 m2)
Renal 9.31 12.53 9.17 11.69
Total 66.78 12.63 65.31 11.98
Initial body temperature, C
mean SD
37.6 0.3 37.8 0.2
Initial dialysate leukocyte
counts, mL
(% neutrophils), mean SD
1,063.2 532.1
(84.1 7.3)
1,102.6 498.3
(86.0 5.7)
Initial blood leukocyte counts, mL
(% neutrophils), mean SD
9,521.4 889.4
(75.4 5.8)
9,428.6 825.9
(77.2 5.7)
Differences between groups are not statistically significant.
CGN¼ chronic glomerulonephritis; HUS¼ hemolyticeuremic syndrome;
PCK¼ polycystic kidney disease; SD¼ standard deviation; wCCr¼weekly
creatinine clearance.responses to treatment and 13 with delayed responses. The two
groups were similar in mean age, gender, initial body
temperature, initial dialysate leukocyte counts, initial blood
leukocyte counts, dialysis duration, peritonitis rate, serum
albumin concentration, and adequacy of dialysis before bouts
of peritonitis, as indicated by fractional clearance of urea as
a function of its distribution volume (Kt/Vurea) and weekly
creatinine clearance. In the rapid response group, 56% of the
microorganisms causing peritonitis were Gram-positive, 32%
were Gram-negative, and in 12%, the cultures remained
negative. In the delayed response group, the distribution of
microorganisms was 53.8% of Gram-positive, 30.8% of Gram-
negative, and 15.4% of negative cultures, not significantly
different from that associated with the rapid response group
(Table 2).3.2. Levels of IL-17 in PDE during peritonitis and
correlation with treatment outcomeThe longitudinal levels of IL-17 in PDE during peritonitis
are shown in Fig. 1. In the rapid response group, high levels of
IL-17 cytokine were detected in PDE on Day 0, which
progressively decreased during treatment. In the delayed
response group, IL-17 cytokine levels in PDEwere significantly
lower than those in the rapid response group on Days 0e3 and
remained at a low level throughout the next 6 days. Through
Days 0e3, the levels of IL-17 in PDE were significantly higher
in the rapid response group as compared with the delayed
response group ( p< 0.05). On Days 4e9, there were no
statistically significant differences in the level of IL-17 between
the rapid and delayed response groups; however, the level of IL-
17 tended to be slightly lower in the rapid response group.
A rapid clinical response indicates resolution of symptoms
of peritonitis and clearing of the PDE within 72 hours of
initiation of antibiotic therapy; we further divided the perito-
nitis clinical course into early phase (Days 0e3) and late
phase (Days 4e9). During the early phase of peritonitis (DaysTable 2
Organisms isolated during peritonitis episodes in rapid and delayed response
groups
Microorganisms Rapid response
group (n¼ 25)
Delayed response
group (n¼ 13)
Gram-positive organisms
Staphylococcus epidermidis 6 3
Other coagulase-negative
Staphylococcus spp.
3 2
Staphylococcus aureus 2 1
Streptococcus spp. 2 d
Enterococcus spp. 1 1
Total 14 (56.0%) 7 (53.8%)
Gram-negative organisms
Pseudomonas aeruginosa 1 1
Escherichia coli 3 2
Proteus spp. 2 d
Klebsiella spp. 2 1
Total 8 (32.0%) 4 (30.8%)
Culture negative 3 (12.0%) 2 (15.4%)
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Fig. 1. Levels of interleukin (IL)-17 in peritoneal dialysis effluents (PDE)
during peritonitis. Serial changes in IL-17 levels in PDE during peritonitis.
Data are mean standard deviation values. *p< 0.01 for rapid versus delayed
clinical response.
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the rapid response group as compared with those of the
delayed response group ( p< 0.05) (Fig. 2). On Days 4e9,
there were no statistically significant differences in the levels
of IL-17 between the rapid and delayed response groups
(Fig. 2). These results indicated that patients in the rapid
response group had high levels of IL-17 in PDE during the
early phase of peritonitis, and this cytokine provided signifi-
cant protection in the early peritoneal immune response.
4. Discussion
In the present study, we report that the dialysis effluent of
PD patients with clinical peritonitis contains significant levels
of IL-17. Our data indicate that local IL-17 production is part
of a protective early immune response to PD-related0-3 day 4-9 day
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Fig. 2. Levels of interleukin (IL)-17 in peritoneal dialysis effluents (PDE)
during the early and late phases of peritonitis. During the early phase of
peritonitis (Days 0e3), the levels of IL-17 in PDE were significantly higher in
the rapid response group. During the late phase of peritonitis (Days 4e9),
there were no statistically significant differences in the level of IL-17 between
the rapid and delayed response groups. Data are mean standard deviation
values. *p< 0.01 for rapid versus delayed clinical response.peritonitis. IL-17 is a potent proinflammatory cytokine; its
differential response in relation to treatment outcome has not
been previously reported with respect to peritoneal immunity.
This study provides evidence that locally produced IL-17 may
play an important role in regulating the peritoneal host defense
against PD-related peritonitis.
Increasing evidence suggests that IL-17 may significantly
affect neutrophil maturation and promote their generation,
migration, and accumulation.17,24 IL-17 plays an important
role in neutrophil homeostasis and recruitment; however, its
role in peritoneal inflammatory response is not clear. A
previous study demonstrated that IL-17 possesses a significant
potential to recruit neutrophils into the peritoneum.23 Our
results showed that, in the rapid response group, the produc-
tion of IL-17 in PDE was high initially and progressively
decreased during treatment. In contrast, the level of IL-17
remained low during the whole course in the delayed response
group. Although the expression of IL-17 coincided with
neutrophil appearance in PDE in the rapid response group, it
was not correlated in the delayed response group. These
findings suggested that IL-17 may affect the peritonitis
outcome through an immune response other than innate
(neutrophil recruitment) immunity.
Recent studies showed the importance of IL-17 in the
induction of Th1 and Th2 immune response.19 IL-17/Inter-
feron (IFN)-g double-positive T cells are found in both human
and mouse inflammed tissues.20e22,25 Under IL-12 stimula-
tion, these populations can be stimulated to Th1-like cells. A
recent study also showed that IL-17 can promote Type 1 T-cell
immunity against pulmonary intracellular bacterial infec-
tion.18 In our previous study,9 a Type 1 T-cell response was
found to be critical for favorable outcome after peritonitis
treatment. We found that IL-12 and IL-18 together exert
a synergistic effect on IFN-g production by Th1 cells. The
presence of IFN-g during the early stages of infection is
critical for the development of a strong Type 1 T-cell response
to infection. In the present study, patients in the rapid response
group had high levels of IL-17 in PDE during the early phase
of peritonitis. These results indicate that IL-17 cytokine,
similar to IL-12 and IL-18, provided significant protection in
the early peritoneal immune response. Further study will focus
on how the IL-17 cytokine modulates the peritoneal Th1/Th2
immune response and on its interaction with IFN-g during
peritoneal infection.
IL-17 is the hallmark of Th17 cells. Th17 has been thought
to be a distinct effecter of T-cell subsets in the recent years.26
Besides IL-17, Th17 cells can express a heterogeneous cyto-
kine profile, including IL-17A, IL-17F, IL-22, IL-26, CC
chemokine ligands (CCL)-20, and IFN-g.27 Previous studies
showed the involvement of IL-17/Th17 in host defense against
bacterial infection.28e30 Some other studies suggest some
relationship between the Th17 and the Th1 differentiation
program.21,22,25 In this study, we found significant levels of IL-
17 in the PDE of PD patients with peritonitis. The expression
pattern of IL-17 correlated with treatment outcome, and the
local IL-17 production showed a protective early immune
response. However, it remains unclear which cells are the major
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Further studies to delineate the peritoneal Th17 cells and the
relationship between the peritoneal Th17 and Th1 subsets will
provide new insights into how peritoneal inflammation and
outcome are modulated.
Peritonitis is a local inflammatory disorder. All of the resi-
dent peritoneal cavity cells as well as the leukocytes that are
recruited and infiltrate, coordinate the immune response asso-
ciated with peritoneal infection.11,12 IL-17 serves as a potential
link between the innate and adaptive immune responses during
bacterial peritoneal infection. During the initial stages of
bacterial peritoneal infection, IL-17 can recruit innate immune
cells and stimulate proinflammatory cytokine production.
Subsequently, IL-17 can shape the nature of the adaptive
immune response by T cells. The results from this study
demonstrated that during the early phases of peritonitis, high
levels of IL-17 correlated with good treatment response.
However, the role of IL-17 during the later phases of peritonitis
remained unclear. Combined with our current results, addi-
tional studies delineating the role of IL-17 at different phases of
peritonitis will enhance our understanding of the innate and
adaptive immune mechanism during peritoneal inflammation.
In conclusion, the present study found that local IL-17
production was part of a protective early immune response to
PD-related peritonitis. The expression pattern of IL-17 in PDE
may determine the outcome of peritonitis in PD patients. Our
results could have implications for designing therapeutic
interventions aimed at the manipulation of early cytokine
cascades in patients with peritonitis. These findings enhance
our understanding of the peritoneal immune response and
facilitate the development of new strategies for peritonitis
treatment.
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